PHARMACY

Verde launches Deterra drug disposal pilot in Delaware

BY DSN STAFF

MINNEAPOLIS — Verde Technologies has announced a pilot program for its Deterra Drug Deactivation System that will see the company partner with the Delaware Prescription Action Committee (PDAC) and the Delaware Pharmacists Society to combat prescription drug abuse.

Deterra uses Verde’s Molecular Absorption Technology, which is a carbon that bonds to pharmaceutical compounds when water is added, neutralizing a drug’s active ingredient and allowing the bag to be thrown away. The product will allow Delaware residents — where since 2010 more people have died from drug overdoses than any other accidental cause — to dispose of oft-abused medication quickly without risk of them entering the water supply or landfills.

“We must take a multi-faceted approach to reducing prescription drug abuse in Delaware”" said Dr. Karyl Rattay, co-chair of the PDAC and Delaware Division of Public Health director. “Safe and secure disposal is a vital part of keeping drugs out of the hands of the wrong people and protecting our water supply. This statewide pilot is an important step in the right direction.”

Starting Aug. 18, Verde will work with pharmacists to provide 1,200 residents with qualifying prescriptions free Deterra packages that will allow them to deactivate any unused prescription medication, particularly opioids. Pharmacists will also receive training to teach residents about safe medication deactivation and disposal.

“Pharmacists play a critical role in reducing prescription drug abuse by practicing responsible dispensing of painkillers and educating patients, and now the new Deterra program provides us all with a proven tool to empower patients to safely deactivate and dispose of leftover medications at home,” said Hooshang Shanehsaz, Division of Services for Aging and Adults with Physical Disabilities pharmacy director. “It offers a convenient, cost-effective way to remove medications from the home, and ultimately prevent prescription drug abuse from starting.”

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

PHARMACY

TruTag, WuXi PharmaTech successfully test edible, on-dose authentication

BY David Salazar

SHANGHAI and HONOLULU — Testing on an edible on-dose authentication technology developed by TruTag Technologies is showing promising results for its use in combatting counterfeit drugs. 
 
TruTech partnered with WuXi PharmaTech, a research and development capability and development company, to test its technology that can store a drug’s provenance information on individual tablets. The silica, dust particle-sized TruTags act like bar codes that can provide information about where a drug was manufactured and its dosage, as well as supply chain details like lot or batch number. 
 
“One can think of TruTags as a form of edible PIATS, or Product Identification Authentication Tracking System, which can be embedded into a product like unique fingerprints,” TruTag Technologies founder and Chairman Hank Wuh said. “With our ability to securely identify individual goods without labels or packaging, we aim to dramatically improve the safety and traceability of critical products such as food and medicine and in the process to have a fundamental impact on big data.”
 
The testing that WuXi and TruTag completed showed that the technology can be applied to certain solid oral dosage form product without new equipment or changes in the manufacturing process. Tags stay with the tablet and are undetectable except to TruTag’s optical detection device. 
 
“We have demonstrated the ability of our technology to integrate an edible and safe identification code directly into an oral solid drug, thereby indelibly marking the product with an internal code for its lifetime,” TruTag President Kent Mansfield said. “In the near term, this will allow drug manufacturers and distributors to have the ultimate audit of a drug's provenance and origin without reliance on packaging or laboratory chemical analysis.”

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

PHARMACY

Mylan extends EpiPen4Schools program

BY David Salazar

PITTSBURGH — Three years after it launched its EpiPen4ASchools program, Mylan announced this week that it would continue through the 2015-2016 school year. Since the anaphylaxis awareness program began, more than 56,000 schools have enrolled in EpiPen4Schools. 

"As we reflect on the first three years of the program, we are proud of the progress made to enhance anaphylaxis preparedness in schools across the country," Mylan CEO Heather Bresch said. “Up to 25% of anaphylaxis cases at school occur in those who have not been previously diagnosed with a life-threatening allergy, so we encourage eligible schools to enroll before students return this fall." 

Schools who participate in the program are eligible to receive either four free EpiPen or EpiPen Jr auto-injectors, a storage unit called the EpiLocker and a training video on identifying and treating anaphylaxis that also instructs on how to properly use an EpiPen epinephrine injector. Schools can also receive an EpiPen trainer to practice, and a poster with anaphylaxis info 

"This past school year, EpiPen® Auto-Injectors provided by the EpiPen4Schools program were used in two incidents,” said Connie Trent, the Health Services Facilitator for Forsyth County Schools in Cumming, Ga. "It is of utmost importance that school personnel are able to act quickly, and with the support and training resources provided through EpiPen4Schools, our staff is prepared to respond."

A recent online survey of some 6,000 participating schools found that 48.7% of anaphylactic events were treated with and EpiPen from the EpiPen4Schools program. For more information on the program, click here.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES